Biological ageing and healthspan endpoints — indication assessment
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
§1Assessment
§1.1Definition
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Epigenetic age acceleration
- Frailty index
- Functional capacity
- All-cause mortality
§1.3State of the evidence
The Institute assesses 9 compounds in this indication, drawing on 4 trial records and 1 evidence synthesis. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 · PMID 25738459
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q3C(R9) Impurities: Guideline for Residual Solvents. ICH Harmonised Guideline 2024;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.